Acumen Pharmaceuticals (ABOS) executive compensation, 2026 proxy

Daniel O’Connell, Chief Executive Officer, was paid $1.9M in 2025, down 61% from $4.8M the year before.

Filed
April 23, 2026
Annual meeting
June 3, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.9M-61% vs prior year
CEO pay in equity
48%$890,820 in awards
CEO Base Salary
$646,354Fiscal 2025 base salary
CEO Target Bonus
55%Expressed as percentage of base salary
Corporate Goal Attainment
86%For 2025 annual bonus payout

How O’Connell was paid

$1.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary35%Stock awards22%Option awards26%Non-equity incentive16%All other compensation1%

Named executive officers

ExecutiveTotal
Daniel O’ConnellChief Executive Officer$1,863,567
Matthew ZugaChief Financial Officer and Chief Business Officer$948,789
Jim DohertyPresident and Chief Development Officer$1,012,859

What changed and why

  • $1.9MChief executive officer total compensation decreased to $1,863,567 in fiscal year 2025 from $4,780,687 in fiscal year 2024.
  • Annual base salaries for executive officers were increased for fiscal year 2026 based on performance and market reviews.
  • 86%Corporate performance goal attainment was determined to be 86 percent for fiscal year 2025.
  • Named executive officers received annual equity grants consisting of stock options and restricted stock units.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.